Viewing Study NCT06162559


Ignite Creation Date: 2025-12-24 @ 2:52 PM
Ignite Modification Date: 2026-02-12 @ 8:21 AM
Study NCT ID: NCT06162559
Status: RECRUITING
Last Update Posted: 2024-01-11
First Post: 2023-11-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Sponsor: The Netherlands Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module